Summary
Introduction
Because of the high sensitivity of conventional T 2 -weighted MRI for depicting focal lesions in the brain of multiple sclerosis patients, this technique may provide an objective tool for disease monitoring . Disappointingly, the correlation between the number of focal brain lesions and disability measures like the expanded disability status scale (EDSS) is weak (Filippi et al., 1995b) , limiting the use of MRI for follow-up of patients. A reason for this clinicoradiological paradox may be that brain lesions are sometimes located in clinically silent areas. Spinal cord lesions more often cause symptoms than do brain lesions Thorpe et al., 1996) . However, when combining lesions of both brain and spinal cord, the correlation with EDSS remains weak (Kidd et al., 1993) . This may be caused by lack of histological specificity of conventional T 2 -weighted MRI. T 1 -weighted MRI seems to be more specific than T 2 -weighted MRI for detecting clinically relevant lesions (van Walderveen et al., 1995; Truyen et al., 1996) .
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Another contributor to the clinicoradiological paradox in multiple sclerosis may be underestimation of the disease burden, since, apart from focal lesions, generalized changes may develop in normal-appearing white matter of the brain (Loevner et al., 1995; Gasperini et al., 1996) . Recently, generalized involvement was also suggested in the spinal cord (Lycklama à Nijeholt et al., 1997) . The occurrence of brain (Aschoff et al., 1984; Losseff et al., 1996b) and spinal cord (Kidd et al., 1993; Filippi et al., 1994; Losseff et al., 1996a; Lycklama à Nijeholt et al., 1997) atrophy further supports the concept of generalized multiple sclerosis involvement.
Clinical subtypes of multiple sclerosis differ considerably regarding MRI findings, which influences the relationship between disability and MRI. Relapsing-remitting multiple sclerosis is characterized by the presence of active lesions, seen as a high number of gadolinium-DTPA enhancing lesions . Secondary progressive multiple sclerosis is associated with the presence of large confluent hyperintense brain lesions on T 2 -weighted MRIs (Thompson et al., 1991) . Further, in secondary progressive multiple sclerosis these lesions may partly appear as hypointense on T 1 -weighted MRIs (van Walderveen et al., 1995) . Primary progressive multiple sclerosis patients have relatively few brain lesions, which are small, despite frequent severe disability (Thompson et al., 1990 (Thompson et al., , 1991 . Secondary progressive and primary progressive multiple sclerosis patients may have cervical cord atrophy and, especially in primary progressive multiple sclerosis, diffuse signal changes of the spinal cord (Kidd et al., 1993; Filippi et al., 1996; Lycklama à Nijeholt et al., 1997) .
A large study combining various brain and spinal cord MRI parameters in all three subtypes of multiple sclerosis has not yet been performed. Therefore, we performed such a study in order to study (i) relationships between various MRI parameters, and (ii) the correlation between combined MRI findings and clinical parameters.
Patients and methods
Ninety-one patients (28 relapsing-remitting, 32 secondary progressive and 31 primary progressive) fulfilling the diagnosis of clinically definite multiple sclerosis were recruited from the out-patient clinic of the department of neurology of our hospital. Each patient gave informed consent after the procedures had been explained. The study was approved by the institutional review board of the Vrije Universiteit Hospital, Amsterdam and the Radboud Academic Hospital, Nijmegen, The Netherlands, in accordance with the Helsinki declaration.
Patients were examined by one neurologist, who was unaware of the MRI appearance. Disability was assessed using the EDSS (Kurtzke, 1983) and the functional systems scale (FSS) (Kurtzke, 1961) . The amount and type of urological complaints were scored using a 15-point urological questionnaire, ranging from 0 to 27 (Appendix 1).
MRI
MRI was performed at 1.0 T (Magnetom Impact; Siemens, Erlangen, Germany), immediately after administration of gadolinium-DTPA (0.1 mmol/kg). MRI of the brain consisted of proton density-and T 2 -weighted conventional spin echo [2300/45,90/1 (TR/TE excitations)] and T 1 -weighted conventional spin echo (600/15/2) pulse sequences. Twentyone axial slices were obtained, with an in-plane resolution of~1 mm, a slice thickness of 5 mm and an interslice gap of 0.5 mm. MRI of the spinal cord was performed using a spinal phased array coil. Sagittal slices (slice thickness 3 mm, interslice gap 0.3 mm) were acquired using cardiac-triggered conventional spin echo (2200/20,80/1; proton density-and T 2 -weighted) and T 1 -weighted spin echo (550/15/2). The field of view was 240ϫ480 mm and the imaging matrix was 256ϫ512, yielding pixels of 0.94 mm 2 . One 5 mm thick slice was acquired perpendicular to the spinal cord at C2 level, using T 2 *-weighted gradient echo [620/20/20E/4 (TR/ TE/flip angle/excitations)]. In-plane resolution was 0.90 mm for this sequence. Total MRI acquisition time was~1 h.
Analysis
Focal lesions in the brain and spinal cord were defined as areas of hypointensity (T 1 -weighted images) or hyper-intensity (T 2 -weighted images) sharply demarcated from surrounding tissue. Focal lesions were counted and marked on hard copies by one experienced reader, who was blinded to clinical data. In addition, brain and spinal cord MRIs were scored for the presence of diffuse abnormalities, defined as poorly demarcated high signal areas as seen on both proton density and T 2 images. Scoring was performed by two readers by consensus. In the brain the presence or absence of diffuse abnormalities was scored, and in the spinal cord the length of diffuse abnormalities, expressed as the number of vertebral segments involved, was scored.
The volume of previously identified focal brain lesions was calculated on a workstation (Sun, Mountainview, Calif., USA) using home-developed semiautomated local thresholding software, by a single observer. The T 1 and T 2 lesion volumes (cm 3 ) were calculated by adding the areas of all lesions and multiplying by slice thickness and interslice distance.
The area of brain ventricles was measured on T 1 -weighted MRIs, using local thresholding software. Total brain ventricular area was measured on all slices showing CSF within the ventricles. Ventricle volume (cm 3 ) was calculated by multiplying total ventricle area by slice thickness and interslice distance. The ventricle volume calculation was performed twice by the same observer with an interval of at least 1 month, and the average of these two measurements was used.
The cross-sectional area of the spinal cord (mm 2 ) was calculated on the axial T 2 *-weighted MRI at level C2 by one observer using local thresholding. Cross-sectional area calculation was performed twice with an interval of at least 1 month, and the average of two measurements was used.
Contrast measurements were performed on proton densityweighted brain images. Regions of interest were placed in the periventricular white matter (not in focal lesions) and in adjoining CSF of lateral ventricles by a single observer who was unaware of clinical data. If a diffuse periventricular signal increase was present, the region of interest was directed within such an area. Contrast ratios were calculated by dividing the signal intensity of brain tissue by the signal intensity of CSF.
Comparisons between subtypes of multiple sclerosis and between different types of MRI abnormalities were made using Student's t test for normally distributed data, while the Mann-Whitney U test was used for non-parametric data. Intra-observer variability was expressed as the mean of the absolute difference between two measurements divided by the mean of two measurements. Correlations were calculated as Spearman's rank correlation coefficient. Multiple regression analysis (forward) was performed using EDSS and the urology score as the dependent variable and several brain and spinal cord MRI parameters as independent factors. For correlation coefficients and multiple regression analysis, a P value of less than 0.01 was considered statistically significant, while a value between 0.01 and 0.05 was considered a trend.
Results
Clinical data for each clinical subgroup are listed in Table 1 . Median age of both secondary progressive and primary progressive patients was higher than that of relapsingremitting patients, and disease duration was longer. Further, the median EDSS of secondary progressive and primary progressive patients was higher than that of relapsingremitting multiple sclerosis patients. Scores for symptoms associated with spinal cord abnormalities (FSS subscores for pyramidal, sensory and bowel/bladder symptoms) were significantly higher for secondary progressive and primary progressive than for relapsing-remitting multiple sclerosis. Secondary progressive and primary progressive multiple sclerosis patients had higher urology complaints scores than did relapsing-remitting patients.
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All values are expressed as median (range). Statistics: MannWhitney U test. *P Ͻ 0.001, PP and SP versus RR. RR ϭ relapsing-remitting; SP ϭ secondary progressive; PP ϭ primary progressive; EDSS ϭ expanded disability status scale; FSS ϭ functional systems score. sclerosis subtypes, are listed in Table 2 . Intra-observer variability of the measurements of ventricular volume and spinal cord cross-sectional area were 6 and 3%, respectively. Similarly to clinical findings, considerable differences were present between various multiple sclerosis subtypes regarding brain MRI abnormalities (Figs 1-3 ). Secondary progressive multiple sclerosis patients had significantly higher focal T 1 and T 2 lesion load than did relapsing-remitting and primary progressive multiple sclerosis patients, while the latter two groups did not differ significantly regarding T 1 or T 2 lesion load. The ratio between T 1 and T 2 lesion load was higher in secondary progressive and primary progressive multiple sclerosis patients than in relapsing-remitting multiple sclerosis patients (Table 2 ). The number of gadolinium enhancing brain lesions was slightly, but not significantly, higher in the relapsing-remitting and secondary progressive groups than in the primary progressive group. Diffuse brain abnormalities were found significantly more often in the primary progressive multiple sclerosis group (nine of 31 patients) than in both the relapsing-remitting (three of 28 patients) group and the secondary progressive group (four of 32 patients; χ 2 ϭ 4.8; P Ͻ 0.05). Diffuse brain abnormalities were found mostly in the parietal periventricular white matter (Fig. 3) . The median contrast ratio between the brain white matter and CSF was higher in primary progressive patients than in both relapsing-remitting and secondary progressive patients (Table 2) .
Focal spinal T 1 lesions were not detected in any clinical subgroup. No significant differences were found in the (Table 2) . Diffuse spinal cord abnormalities were found mainly in secondary progressive (10 of 32) and primary progressive multiple sclerosis patients (19 of 31), while they were found in only six of 28 relapsing-remitting patients (χ 2 ϭ 11; P Ͻ 0.01). The presence of diffuse abnormalities in the spinal cord without focal lesions was found mostly in primary progressive patients (10 of 31 patients), while it occurred in only four of 32 secondary progressive patients and in none of relapsing-remitting patients (χ 2 ϭ 15; P Ͻ 0.01). In all patients who had diffuse spinal cord abnormalities without focal lesions, the spinal cord appeared diffusely abnormal at all vertebral levels (Fig. 3) . Median spinal cord cross-sectional area was smallest in the secondary progressive group, followed by the primary progressive and relapsing-remitting groups. Patients who had diffuse spinal cord abnormalities had significantly smaller mean spinal cord cross-sectional area (67 mm 2 ; range 49-82) than did patients with no, or only focal, abnormalities (cross-sectional area ϭ 75 mm 2 ; range 55-96; P Ͻ 0.01).
Correlation between brain and spinal cord abnormalities
Concerning the total study population, a trend towards correlation was found between the number of focal brain T 1 lesions and the number of focal spinal T 2 lesions (r ϭ 0.22; P Ͻ 0.05). No other correlation between brain and spinal cord parameters was found. More specifically, no correlation was found between brain T 1 lesion load and spinal cord cross-sectional area, or between ventricular volume and spinal cord cross-sectional area. However, the presence of diffuse spinal cord abnormalities was associated with the presence of diffuse brain abnormalities. Ten of 35 (28.5%) patients showing diffuse spinal cord abnormalities also showed diffuse brain abnormalities. In contrast, only six of 56 (11%) patients without diffuse spinal cord abnormalities showed diffuse brain abnormalities (χ 2 ϭ 5.0; P Ͻ 0.05). When only patients were considered who had diffuse spinal cord abnormalities without focal lesions, this association even became stronger: six of 14 (43%) patients with only diffuse spinal cord abnormalities also had diffuse brain abnormalities. In contrast, 10 of the remaining 77 patients (13%) showed diffuse brain abnormalities (χ 2 ϭ 7.1; P ϭ 0.015). Further, MRI parameters were correlated locally, as evidenced by correlation between brain ventricular volume and T 1 lesion load (r ϭ 0.57; P Ͻ 0.000), and between the number of spinal cord segments diffusely involved and spinal cord cross-sectional area (r ϭ -0.32; P ϭ 0.003).
Correlation between MRI parameters and clinical symptoms: total study population
Correlation coefficients between MRI parameters and clinical measures are summarized in Table 3 . In general, brain MRI abnormalities showed trends towards correlation with scores for brain symptoms, while spinal cord MRI abnormalities correlated well with spinal cord symptoms, as illustrated by the good correlation between spinal MRI parameters and the urology complaint score. Regarding the EDSS, there were only trends towards correlation between EDSS and brain T 1 and T 2 lesion loads. By contrast, we found a good correlation between EDSS and spinal cord MRI parameters (Table 3) . Based on the correlation coefficients described above, multiple regression analysis was performed, using EDSS and the urology score as dependent variables. This yielded a model which explained 18% of EDSS variance, and which included brain T 1 lesion load and spinal cord cross-sectional area as factors independently contributing to EDSS (Table 4) .
Using the urology score as the dependent variable, only the number of spinal cord segments diffusely involved was included in the model (Table 5) .
Correlation between MRI parameters and clinical symptoms: relapsing-remitting and secondary progressive subtypes
Correlation coefficients between MRI parameters and clinical measures are summarized in Table 6 . When considering relapsing-remitting and secondary progressive patients, the clinicoradiological correlation differed from that in the whole study population. A correlation was found between EDSS and all brain MRI parameters, including ventricle volume (Table 6 ). EDSS further correlated with spinal cord crosssectional area. FSS subscores associated with spinal cord dysfunction correlated well with spinal cord MRI parameters (Table 6) . Spinal cord symptoms, however, also correlated with brain MRI parameters, as illustrated by the correlation between brain MRI parameters and the bowel/bladder FSS subscore (Table 6) .
Multiple regression analysis using EDSS as the dependent variable and the parameters described above as independent variables yielded a model which explained 36% of EDSS variance, and which included brain T 1 lesion load, brain ventricle volume and spinal cord cross-sectional area as factors independently contributing to EDSS (Table 4) . Using the urology score as the dependent variable, the number of spinal cord segments diffusely involved and the T 1 lesion load in the brain were both included in the model (Table 5) .
Correlation between MRI and clinical symptoms: primary progressive subtype
Correlation coefficients between MRI parameters and clinical measures are summarized in Table 7 . None of the brain or spinal cord MRI parameters correlated with EDSS. The urology complaint score, the bowel/bladder score and the No multiple regression model was found which could explain the variance in EDSS for the primary progressive subgroup (Table 4) . Using the urology score as the dependent variable, brain T 1 lesion load was found to explain most of the variance in urology complaint score (Table 5) .
Discussion
From the results of this study we were able to evaluate differences between clinical subgroups in multiple sclerosis with respect to MRI parameters in the brain and spinal cord in a large group of 91 patients. The results confirm previous studies on brain and spinal cord MRI in multiple sclerosis, which showed considerable differences between subgroups (Koopmans et al., 1989; Thompson et al., 1990 Thompson et al., , 1991 Kidd et al., 1993) .
Apart from evaluating conventional MRI parameters, we evaluated two relatively new brain MRI parameters: diffuse abnormalities and ventricular enlargement. Our method for measuring ventricular volume yielded no information about peripheral (cortical) brain atrophy or about cerebellar atrophy. However, the clear differences in ventricular volume between the subgroups and the correlation with clinical parameters suggest that our method sufficed for the purpose of this study. Regarding diffuse brain abnormalities, scoring this MRI Separate analyses were done for the total study population and either the relapsing-remitting and secondary progressive subtypes or the primary progressive subtype. SE ϭ standard error of coefficient; CSA ϭ cross-sectional area; RR ϭ relapsing-remitting; SP ϭ secondary progressive. Separate analyses were done for the total study population and for either the relapsing-remitting and secondary progressive subtypes or the primary progressive subtype. SE ϭ standard error of coefficient; RR ϭ relapsing-remitting; SP ϭ secondary progressive; PP ϭ primary progressive.
parameter may be subjective. Therefore, this parameter was scored by two observers by consensus and we substantiated our findings to contrast measurements. Brain MRIs were scored only for the presence or absence of diffuse brain abnormalities. Theoretically, the quantitation of diffuse areas in the brain could be a better parameter than merely scoring the images for the presence of diffuse abnormalities. Image segmentation of diffuse abnormalities, however, is difficult because of poor delineation of such abnormalities. Other MRI techniques, like magnetization transfer imaging (Filippi et al., 1995a ), histogram analysis (van Buchem et al., 1996 and spectroscopy (Grossman et al., 1992; Miller, 1995; Larsson, 1995; Kimura et al., 1996) , may provide better tools to quantitate diffuse brain abnormalities. Based on our results and on previous studies, MRI characteristics of each subgroup are summarized in Table 8 . Relapsing-remitting multiple sclerosis differs mostly from other subgroups by the relative absence of diffuse abnormalities and of atrophy. Secondary progressive multiple sclerosis may be differentiated from the other subgroups by a larger proportion of brain lesions appearing as hypo-intense on T 1 -weighted MRIs, and by atrophy of both the brain and the spinal cord. Primary progressive patients often have diffuse abnormalities in the brain and spinal cord, while they often have only a few focal lesions despite a high degree of disability.
Relationship between brain and spinal cord abnormalities
Spinal cord atrophy and diffuse signal increase may reflect secondary changes caused by brain abnormalities, as has been reported to occur in Wallerian degeneration (Sawlani et al., 1997) . Our results did not substantiate this theory in multiple sclerosis patients, since these spinal cord MRI abnormalities were not related either to the focal brain lesion load or to ventricular enlargement. Spinal cord abnormalities, however, followed the same pattern in the brain, as indicated by the simultaneous occurrence of diffuse abnormalities in the brain and spinal cord. This suggests that all spinal cord abnormalities found represented local pathology and were not secondary to brain abnormalities.
Relationship between MRI appearance and clinical scores
Since relapsing-remitting and secondary progressive multiple sclerosis may be considered as two phases of the same disease and primary progressive multiple sclerosis may be a separate entity (McDonnell and Hawkins, 1996) , we performed our analysis with respect to these subgroups. The higher EDSS scores in secondary progressive patients compared with relapsing-remitting patients were determined to a large extent by spinal cord symptoms. In agreement with this finding, multiple regression analysis revealed independent contributions to EDSS by both brain and spinal cord MRI parameters. This illustrates the usefulness of integrating MRI of the brain and spinal cord in attempts to explain disability in multiple sclerosis.
In the primary progressive subgroup spinal cord MRI parameters correlated well with spinal cord symptoms, illustrating the importance of spinal cord involvement in primary progressive multiple sclerosis. None of the MRI parameters, however, could explain EDSS in primary progressive multiple sclerosis. This may have been caused by lack of variance in EDSS in this group. Alternatively, current MRI methods may not represent the full extent of the disease process. Since we did not quantitate the amount of diffuse brain involvement we may have underestimated the amount of brain abnormalities. New techniques for the quantitation of generalized brain involvement in multiple sclerosis, such as magnetization transfer histogram analysis and spectroscopy (Loevner et al., 1995; van Buchem et al., 1996) , may improve the clinicoradiological correlation in primary progressive multiple sclerosis. Also, these new MRI methods may further improve the clinicoradiological correlation in relapsing-remitting and secondary progressive multiple sclerosis, since our combined parameters still explained only 36% of EDSS variance in these subtypes.
In conclusion, the integration of MRI findings for the brain and spinal cord indicates that different clinical courses may be associated with distinct MRI patterns in multiple sclerosis.
In relapsing-remitting and secondary progressive multiple sclerosis, disability can be explained at least partly by features revealed by the currently available MRI techniques. Brain abnormalities seem to explain most of the symptoms and disability in these subtypes, while in primary progressive multiple sclerosis spinal cord abnormalities seem to be clinically more important than brain abnormalities. Finally, our results indicate that brain and spinal cord abnormalities may develop independently of each other in multiple sclerosis.
